Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year mark
Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Healio2d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
MPR1d
Week 52 Data Show Inebilizumab Continues to Benefit in AChR+ Myasthenia Gravis
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen reports new data from Phase 3 registrational MINT trial of Uplinza
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
The Pharma Letter1d
Amgen’s Uplizna impresses in gMG ahead of filing
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Medscape17d
Divergence of Allosteric Effects of Rapacuronium on Binding and Function of Muscarinic Receptors
Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular blocker ...